Heart Failure (HF)
Patient Condition
Hypertensive heart disease with HFrEF, LVEF 32%, NYHA class III, long-term poor control of hypertension leads to left ventricular hypertrophy and dilation. Concurrent type 2 diabetes and chronic kidney disease (eGFR 55 mL/min).
Treatment Timeline
| Phase | Details | Date |
|---|---|---|
| multidisciplinary assessment | ||
| ARNI+SGLT 2i launch | ||
| Integrated metabolic management | ||
| Maintenance and follow-up |
Treatment Outcome
| before | LVEF 32%, NYHA class III, NT-proBNP 3600 pg/mL, HbA1c 8.2%, eGFR 55 mL/min |
|---|---|
| after | LVEF 48%, NYHA class I-II, NT-proBNP 980 pg/mL, HbA1c 6.8%, eGFR 52 mL/min |
| highlight | ARNI+ SGLT2i achieves triple benefits in cardiac function, blood sugar, and renal function in patients with cardiorenal metabolic syndrome |